CTOs on the Move

CytoDyn

www.cytodyn.com

 
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cytodyn.com
  • 1111 Main Street Suite 660
    Vancouver, WA USA 98660
  • Phone: 360.980.8524

Executives

Name Title Contact Details
Nitya Ray
Chief Technology Officer Profile

Funding

CytoDyn raised $15M on 03/31/2020

Similar Companies

PharmSource Information Services

PharmSource Information Services is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ThinSpring

ThinSpring is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advitech

Advitech is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cybrexa

Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company`s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology.

Genosco

Genosco is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.